异动解读 | Apellis Pharmaceuticals Inc.盘前大跌14%,业绩不佳拖累股价

异动解读
05 Nov 2024

生物制药公司Apellis Pharmaceuticals Inc. (APLS)股价在2024年11月5日盘前大跌14.11%,引发市场关注。这一大幅下跌或与该公司近期公布的第三季度业绩不佳有关。

APLS第三季度亏损46美分/每股,远超预期的30美分/每股。该公司第三季度营业收入为1.968亿美元,也低于2.0035亿美元的预期。业绩低于预期导致投资者对公司前景失去信心,抛售该股。

另一个重要因素是APLS旗舰产品SYFOVRE注射液遭到欧盟人用药委员会否定,给公司业务前景带来不确定性。SYFOVRE是一款治疗地理性黄斑变性疾病的创新产品,其销售在第三季度也出现下滑,进一步拖累了公司业绩。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10